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Comparative Molecular Field Analysis (CoMFA) and Com-
parative Molecular Similarity Indices Analysis (CoMSIA)
were performed on a series of 5-aryl-2,2-dialkyl-4-phenyl-
-3(2H)-furanone derivatives, as selective cyclooxygenase-
-2 (COX-2) inhibitors. Ligand molecular superimposition
on the template structure was performed by the atom/
shape based root mean square fit and database alignment
methods. Removal of three outliers from the initial train-
ing set of 49 molecules improved the predictivity of the
model. The statistically significant model was establish-
ed of 36 molecules, which were validated by a test set of
ten compounds. The atom and shape based root mean
square alignment (IV) yielded the best predictive CoMFA
model R2cv = 0.664, R2 (non-cross-validated square of
correlation coefficient) = 0.916, F value = 47.341, R2bs =
0.947 with six components, standard error of prediction36
= 0.360 and standard error of estimate36 = 0.180 while
the CoMSIA model yielded R2cv = 0.777, R2 (non-cross-
-validated square of correlation coefficient) = 0.905, F va-
lue = 66.322, R2bs = 0.933 with four components, standard
error of prediction36 = 0.282 and standard error of esti-
mate36 = 0.185. The contour maps obtained from 3D-
-QSAR studies were appraised for activity trends for the
molecules analyzed. Results indicate that steric, electro-
static, hydrophobic (lipophilic) and hydrogen bond donor
substituents play a significant role in COX-2 inhibitory
activity and selectivity of the compounds. The data ge-
nerated from the present study will further help design
novel, potent and selective COX-2 inhibitors.
Keywords: 3D-QSAR, CoMFA, CoMSIA, cyclooxygenase-
-2 inhibitors, anti-inflammatory agents
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Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to alleviate the
symptoms of inflammatory diseases (1, 2). The principal pharmacological effects of NSAIDs
are due to their ability to inhibit prostaglandin synthesis by blocking cyclooxygenase
(COX), which catalyses the conversion of arachidonic acid to PGH2 (3). The discovery of
two isoforms (4), COX-1 and COX-2, helped in understanding the side effects associated
with NSAIDs. COX-1 is a constitutive enzyme and is necessary for proper functioning of
the kidney and stomach. In contrast, COX-2 is an inducible isoform that leads to inflam-
mation (5, 6). Classical NSAIDs like aspirin, ibuprofen, flubriprofen and naproxen in-
hibit both forms of COX and cause gastric ulceration and renal failure (7–10). It is there-
fore expected that selective inhibition of COX-2 will provide a new generation of NSAIDs
with significantly reduced side effects.
A large number of research studies aimed at finding selective COX-2 inhibitors were
reported earlier (11–14). Many studies have been carried out using computer simulations
to develop protocols and methods for designing new COX-2 inhibitors such as oxazoles,
pyrazoles, pyrroles and imidazoles (15–19). Furthermore, selective COX-2 inhibitors are
believed to play a vital role in ovulation and labor as well as in the treatment of colon
cancer and Alzheimer’s disease. Recently, rofecoxib has been banned from the market
because of its serious side effects (20). Hence, there is a need to analyze the pharma-
cophore present in these compounds using the Three Dimensional Quantitative Struc-
ture Activity Relationship (3D-QSAR) methods.
Quantitative structure-activity relationship (QSAR) enables the investigators to es-
tablish reliable quantitative structure-activity and structure-property relationships to derive
an in silico QSAR model to predict the activity of novel molecules prior to their synthe-
sis. 3D-QSAR methodology has been successfully used to generate models for various
chemotherapeutic agents.
In order to study and deduce a correlation between structure and biological activity
of 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives as selective COX-2 inhibitors,
we have developed 3D-QSAR CoMFA/CoMSIA models for the series of 5-aryl-2,2-di-
alkyl-4-phenyl-3(2H)-furanones (21). Together with the contour maps derived, they re-
vealed the significance of steric, electrostatic, hydrophobic and hydrogen bond donor
fields. Structural variations in the molecular fields of particular regions in the space




Series of 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives have been reported
as selective COX-2 inhibitors (21). In vitro assay for COX-2 inhibition was performed us-
ing the human whole blood method. The negative logarithm of the inhibition values
–log IC50, i.e., pIC50, was used in 3D-QSAR. Tables I–III define the structure and biologi-
cal activity of the training set and test set compounds. The robustness and predictive
ability of the models were evaluated by selecting a wide range of biological activities
with chemical classes similar to the training set.
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Table I. Structures and biological activities of the training and test sets of molecules





1 Phenyl CH3 CH3 CH3 7.30 7.24 7.11
2 3-Fluorophenyl CH3 CH3 CH3 7.69 7.59 7.32
3 3-Chlorophenyl CH3 CH3 CH3 8.00 6.28 6.60
4 4-Bromophenyl CH3 CH3 CH3 7.52 7.59 7.70
5c 3-Chloro-4-fluorophenyl CH3 CH3 CH3 6.52 7.81 7.67
6 3,5-Difluorophenyl CH3 CH3 CH3 7.30 7.51 7.34
7 3,5-Dichlorophenyl CH3 CH3 CH3 7.52 7.71 7.68
8c 3-(Trifluoromethyl)-phenyl CH3 CH3 CH3 7.30 7.96 7.63
9 3-i-Propylphenyl CH3 CH3 CH3 7.52 7.52 7.59
10 4-i-Propylphenyl CH3 CH3 CH3 7.52 7.47 7.43
11c 4-n-Butylphenyl CH3 CH3 CH3 8.69 7.34 7.25
12 3-Acetylphenyl CH3 CH3 CH3 7.30 7.44 7.15
13 4-Acetylphenyl CH3 CH3 CH3 6.52 6.68 6.68
14 3-Methoxyphenyl CH3 CH3 CH3 7.00 7.03 7.03
15 Phenyl CH3 C2H5 CH3 6.69 6.74 6.84
16 2-Fluorophenyl CH3 C2H5 CH3 6.52 6.72 6.79
17 3-Chlorophenyl CH3 C2H5 CH3 7.52 7.31 7.32
18 3,5-Dichlorophenyl CH3 C2H5 CH3 7.52 7.34 7.40
19 3-(Trifluoromethyl)-phenyl CH3 C2H5 CH3 7.30 7.33 7.40
20c 3-Methoxyphenyl CH3 C2H5 CH3 6.52 7.68 6.79
21 Phenyl C2H5 C2H5 CH3 6.69 6.82 6.92
22 4-(Trifluoromethyl)-phenyl C2H5 C2H5 CH3 7.52 7.55 7.42
23c 3-Methylphenyl C2H5 C2H5 CH3 6.30 7.09 7.19
24 4-Methylphenyl C2H5 C2H5 CH3 7.52 7.33 7.17
25 Phenyl CH3 CH3 NH2 8.09 7.96 8.13
26 3-Fluorophenyl CH3 CH3 NH2 8.52 8.53 8.35
27 3,4-Difluorophenyl CH3 CH3 NH2 8.15 7.05 7.25
28c 3-(Trifluoromethyl)-phenyl CH3 CH3 NH2 7.95 8.89 8.67
29 4-Acetylphenyl CH3 CH3 NH2 7.88 7.61 7.70
a Biological activity (µmol L–1) expressed as –log IC50 against human COX–2 enzyme.
b Calculated activity from alignment IV.








Ar – aromatic group
Molecular modeling
All molecular modeling and 3D-QSAR studies were performed using the molecular
modeling package SYBYL 6.9 (22) with standard Tripos force field (23) at the Silicon Graph-
ics Fuel workstation. The X-ray crystallographic data for this ligand-COX-2 complex are
not deposited in the protein data bank; hence all the molecules were constructed using
the standard geometry and bond lengths with SYBYL. The initial optimization was car-
ried out using the standard TRIPOS force field employing the Gasteiger Marsili charges;
the constraints were removed and repeated minimization was performed using the steepest
descent and conjugated gradient method until the RMSD (root mean square deviation)
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30c 2 H CH3 7.52 7.21 7.24
31c 3-F CH3 7.52 7.18 7.32
32 3-Cl CH3 7.69 7.74 7.68
33 3-F, 5-F CH3 7.52 7.58 7.42
34c 3 H CH3 7.52 6.64 7.11
35 3-F CH3 7.52 7.09 7.32
36 3-Cl CH3 7.36 7.20 7.59
37c 3-F, 5-F CH3 7.52 6.95 7.33
38c 2 H NH2 7.52 7.96 8.40
39 3-F NH2 8.52 8.55 8.62
40 3-F, 5-F NH2 8.52 8.45 8.64
41 3 H NH2 7.52 7.45 7.45
42 3-F NH2 7.52 7.89 7.66
43c 3-F, 5-F NH2 7.69 7.79 7.67
a Biological activity (µmol L–1) expressed as –log IC50 against human COX–2 enzyme.
b Calculated activity from alignment IV.








value of 0.001 kcal mol–1 was achieved. Using MULTISEARCH option in SYBYL 6.9, var-
ious conformers were obtained out of which the lowest energy conformers were selected
for superimposition. Further geometry optimization was performed using MOPAC with
AM1 Hamiltonian (24).
Alignment rules
Molecular conformation and orientation is one of the most sensitive input areas in
3D-QSAR studies. In the present study, superimposition of the molecules was carried
out by different approaches using compound 26 (Table I) as template structure.
Alignment I. – Each analog was aligned to the template by rotation and translation
so as to minimize the RMSD between atoms in the template and the corresponding at-
oms in the analog using the DATABASE ALIGN option in SYBYL.
Alignment II. – In this alignment, atoms of the molecules were used for RMS (root
mean square) fitting corresponding to the atoms in the template.
Alignment III. – Here, centroids rather than the exact superimposition of atoms of
the rings were used for RMS fitting to the template.
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44c Phenyl 7.52 7.08 7.12
45 3-Fluorophenyl 6.47 7.93 7.80
46 3-Methylphenyl 7.52 7.36 7.39
47 4-i-Propylphenyl 7.30 7.40 7.44
48 Phenyl 6.30 6.16 6.15
49 3-Methylphenyl 6.30 6.46 6.46
a Biological activity (µmol L–1) expressed as –log IC50 against human COX–2 enzyme.
b Calculated activity from alignment IV.











Alignment IV. – Here, both atoms and centroids were selected for superimposition
on the template. Fig. 1 shows the superimposition of 49 molecules obtained by align-
ment IV. The atoms and centroids used for alignments are defined in Fig. 2. These align-
ments were subsequently used in CoMFA/CoMSIA probe interaction energy calculations.
CoMFA and CoMSIA studies
The steric and electrostatic field energies were calculated using sp3 carbon as probe
atom. The energies were truncated to ± 30 kcal mol–1. The CoMFA fields generated auto-
matically were scaled by the CoMFA-STD method in SYBYL.
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Fig. 1. Superimposition of 49 molecules



























II 2, 4, 1’, 5, 1’’
III 1*, 2*, 3*
IV 1*, 4, 1’, 5, 1’’
Fig. 2. Alignment rules.
Similarity indices (descriptors) were derived with the same lattice box as used in
CoMFA calculations. Five CoMSIA similarity index fields available within SYBYL steric,
electrostatic, hydrophobic (lipophilic), hydrogen bond donor, hydrogen bond acceptor
were evaluated using the probe atom. Gaussian-type distance dependence was between
the grid point and each atom of the molecule. The default value of 0.3 was used as atten-
uation factor.
Partial least square (PLS) analysis
The CoMFA/CoMSIA descriptors served as independent variables and pIC50 values
as a dependent variable in PLS regression analysis (25) in deducing the 3D-QSAR mo-
dels. Normally, cross-validation is used to check the predictivity of the derived model.
Results of the analyses correspond to a regression equation with thousands of coeffici-
ents. The performance of models was calculated using the leave one out (LOO) cross-
-validation method. The optimum number of components (Nc) used to derive the non
cross-validated model was defined as the number of components leading to the highest
R2 cross-validated and lowest standard error of prediction (SEP). To obtain the statistical
confidence limit in analyses, PLS analysis using 100 bootstrap groups within the opti-
mum number of components was performed.
RESULTS AND DISCUSSION
CoMFA and CoMSIA techniques were used to derive 3D-QSAR models for 5-aryl-
-2,2-dialkyl-4-phenyl-3(2H)-furanones as selective COX-2 inhibitors. The negative loga-
rithm of the in vitro inhibitory activity pIC50 was used as a dependent variable.
The lower energy conformers obtained from the MULTISEARCH option in SYBYL
were used in the study. All the molecules were aligned employing atom/shape based
RMS fitting and RMSD based database fitting techniques. Various 3D-QSAR models
were generated and the best one was selected based on the statistically significant pa-
rameters obtained.
Preliminary studies performed using 39 molecules in the training set reveal the sig-
nificance of CoMFA parameters for the final results. PLS analysis was performed using
varying column filtering values. Finally, column filtering was set to 0.0 kcal mol–1 and
used for further calculations in PLS analysis.
Analysis A shows CoMFA results (Table IV) obtained from four different alignments
using 39 molecules in the training set. Database alignment I showed cross-validated R2 =
0.416 with four components, non cross-validated R2 = 0.809, F value 18.850, bootstrapped
R2 = 0.909; the steric and electrostatic contributions were 70.1 and 29.9%, respectively.
The CoMFAmodel generated from atom based RMS alignment II (Table IV) showed
cross-validated R2 = 0.389 with four components, non cross-validated R2 = 0.846, F value
43.806, bootstrapped R2 = 0.899 with 60.2 steric and 39.8% electrostatic contributions.
The shape based alignment III (Table IV) yielded cross-validated R2 = 0.322 with five
components, non cross-validated R2 = 0.759, F value 35.670 and bootstrapped R2 = 0.806.
The steric and electrostatic contributions were 68.3 and 31.7%, respectively.
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Alignment IV (atom and shape based) yielded a cross-validated R2 = 0.429 with five
components, non cross-validated R2 = 0.822, F value 28.664 and bootstrapped R2 = 0.890.
The steric and electrostatic contributions were 64.3 and 35.7%, respectively.
Since the CoMFA technique is alignment sensitive, differences in statistical values
are observed with different alignments (Table IV). All the CoMFAmodels obtained from
analysis A demonstrated moderate internal and external predictivity. Thus, in order to
increase the predictive power of derived models, further experiments were performed.
Based on the results of the QSAR studies, three molecules (3, 27 and 45) of the training
set with high residual values were omitted from the PLS analysis.
Analysis B (Table V) shows the CoMFA results obtained from four different align-
ments using a training set involving 36 molecules; the model derived showed a better
confidence level in statistical significance.
RMSD based database alignment I showed improved cross-validated R2 value of
0.416–0.502 with five components, non cross-validated R2 = 0.809–0.922, F value 18.850–
34.292 and bootstrapped R2 between 0.909 and 0.969. The steric and electrostatic contri-
butions were found to be 58.2 and 41.8%, respectively. The same trend was observed in
the remaining alignments (Table V), except that for atom-based alignment II the F value
slightly decreased from 43.806 to 40.416. This model displayed an improved cross-vali-
dated R2 of 0.389 to 0.559 with five components, non cross-validated R2 from 0.846 to
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Table IV. Summary of CoMFA results (analysis A)
Alignment Ia IIb IIIc IVd
R2cve 0.416 0.389 0.322 0.429
Ncf 4 4 5 5
SEPg 0.493 0.543 0.540 0.470
R2ncvh 0.809 0.846 0.759 0.822
SEEi 0.284 0.273 0.292 0.262
F value 18.850 43.806 35.670 28.664
P R2 = 0j 0.0 0.0 0.0 0.0
Contrib. steric 70.1 60.2 68.3 64.3
Contrib. electr. 29.9 39.8 31.7 35.7
R2bsk 0.909 0.899 0.806 0.890
SDl 0.034 0.044 0.060 0.039
a Alignment by RMSD database.
b Alignment by atom-based RMS fit.
c Alignment by shape-based RMS fit.
d Alignment by atom and shape-based RMS fit.
e Cross-validated correlation coefficient.
f Number of components.
g Standard error of prediction.
h Non cross-validated square of correlation coefficient.
i Standard error of estimate.
j P R2 = 0, probability that correlation coefficient R equals zero.
k From 100 bootstrapping runs.
l Standard deviation.
0.893 and bootstrapped R2 from 0.899 to 0.913 with 59.4 and 40.6% steric and electro-
static contributions, respectively.
The shape based alignment III (Table V) yielded cross-validated R2 = 0.652 with six
components, non cross-validated R2 of 0.914, R2 value 48.127 and bootstrapped R2 of
0.946. The steric and electrostatic contributions were 59.9 and 40.1%, respectively.
Alignment IV (Table VI) yielded the highest cross-validated R2 of 0.664 with six
components, non cross-validated R2 of 0.916, F value 47.347 and bootstrapped R2 of 0.947.
The steric and electrostatic contributions were found to be 58.1 and 41.9%, respectively.
Thus, all the CoMFA models derived from analysis B showed higher contributions
of steric parameters to the activity of these compounds similar to that of analysis A.
Based on the predictive ability of the four CoMFAmodels from analysis B, alignment IV
was selected for further analysis and all the CoMFA contours were generated using this
model. The graphs of actual vs. fitted and predicted activities for the training and test
sets of molecules are depicted in Figs. 3a and 3b, respectively. The field values generated
at each grid point were calculated as the scalar product of the associated QSAR coeffi-
cient and the standard deviation of all values in the corresponding column of the data
table (STDDEV*COEFF), plotted as the percentage contributions to QSAR equation. The
CoMFA steric and electrostatic contour maps developed using the alignment IV analyses
are shown in Figs. 4a and 4b, respectively.
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Table V. Summary of CoMFA results (analysis B)
Alignment Ia IIb IIIc IVd
R2cve 0.502 0.559 0.652 0.664
Ncf 5 5 6 6
SEPg 0.430 0.405 0.361 0.360
R2ncvh 0.922 0.893 0.914 0.916
SEEi 0.183 0.203 0.179 0.180
F value 34.292 40.416 48.127 47.341
P R2 = 0j 0.0 0.0 0.0 0.0
Contrib. steric 58.2 59.4 59.9 58.1
Contrib. electr. 41.8 40.6 40.1 41.9
R2bsk 0.969 0.913 0.946 0.947
SDl 0.017 0.034 0.025 0.029
a Alignment by RMSD database.
b Alignment by atom-based RMS fit.
c Alignment by shape-based RMS fit.
d Alignment by atom and shape-based RMS fit.
e Cross – validated correlation coefficient.
f Number of components.
g Standard error of prediction.
h Non cross-validated square of correlation coefficient.
i Standard error of estimate.
j P R2 = 0, probability that correlation coefficient R equals zero.
k From 100 bootstrapping runs.
l Standard deviation.
The CoMFA steric map (Fig. 4a) encompasses sterically unfavorable contours (80%
contribution) corresponding to regions in space where steric bulk envisages the decrease
in activity and the polyhedron bordering the furanone ring suggests that bulkier sub-
stituents are not favorable in that region. Conversely, the sterically favorable regions
(20% contribution) observed on the upper side of the 4-phenyl ring in the vicinity of 5’-F
of compound 26 reveal that an increase in activity is anticipated due to the increased
steric bulk. Steric substituents at 3’ and 4’ positions favor the activity (compound 11). In
this compound, the structural flexibility of the n-butyl moiety seems to allow it to ma-
neuver into the ideal space for COX-2 activity and selectivity. However, the sterically
unfavorable contours surrounding 2-position of the furanone nucleus suggested that high
steric bulk reduces the activity (compounds 47–49). Compounds containing the spiro-
cyclopentyl moiety (compounds 44–47) at 2-position in the furanone nucleus showed
better activity compared to compounds 21–24. This may be due to the spirocyclopentyl
moiety occupying a smaller space compared to the diethyl moiety in compounds 21–24.
According to the reported structure of COX-2, there should be a cavity of limited size
available to the 2,2-dialkyl moiety of 3(2H)-furanone COX-2 inhibitors. Spirocyclohexyl
moiety containing compounds (48 and 49) show even poorer activity, which supports
the rationale for »the cavity of limited size near the entrance of COX-2 active site«.
The CoMFA electrostatic map (Fig. 4b), displays contours in the vicinity of 4’-H and
5’-H where the partial negative charge is associated with increased activity (80% contri-
bution). Contours observed in the vicinity of sulfonamide group of 5-phenyl ring (20%
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Table VI. Summary of CoMSIA results
Sa+Eb+Hc S+E+Dd S+E+Ae S+E+D+A H+D+A S+E+D+H S+E+H+A S+D+A Alln
R2cvf 0.635 0.722 0.507 0.705 0.648 0.777 0.641 0.710 0.739
Ncg 3 4 7 3 4 4 6 5 5
SEPh 0.355 0.316 0.445 0.319 0.355 0.282 0.372 0.328 0.311
R2ncvi 0.844 0.852 0.890 0.831 0.901 0.905 0.902 0.819 0.918
SEEj 0.232 0.230 0.210 0.242 0.188 0.185 0.194 0.259 0.175
F value 52.48 40.280 28.766 47.548 63.65 66.322 40.092 24.47 60.145
P R2 = 0k 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
R2bsl 0.880 0.896 0.944 0.848 0.925 0.933 0.946 0.882 0.945




d Hydrogen bond donor.
e Hydrogen bond acceptor.
f Cross-validated correlation coefficient.
g Number of components.
h Standard error of prediction.
i Non cross-validated square of correlation coefficient.
j Standard error of estimate.
k P R2 = 0, probability that correlation coefficient R equals zero.
l From 100 bootstrapped runs.
m Standard deviation.
n All = S+E+D+A+H.
contribution) of compound 26 indicate areas where the electropositive properties of mole-
cules indicate an increase in activity. The electronegative group favoring contours (Fig.
4b) in the vicinity of 3’-H and 4’-H suggest that increased activity is anticipated by elec-
tronegative substituents at positions 3’ and 4’ (compounds 26 and 40), whereas the elec-
tropositive favoring contour indicates low electron density substituents at 4’’-position
favoring activity.
In addition to steric and electrostatic fields, CoMSIA also defines the lipophilicity,
hydrogen bond donor and acceptor fields that are not generally accessible with standard
CoMFA. The atom and shape based alignment IV used in CoMFA studies served as an
alignment for CoMSIA and the results of the study are summarized in Table VI.
The CoMSIAmodel with the combination of all fields yielded a cross-validated R2 =
0.739 with five components, non cross-validated R2 = 0.918, F value 60.145 and bootstrap-
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Fig. 3. Graph of actual vs. calculated
activities from alignment IV (analy-
sis B) of: a) training set molecules,
b) test set molecules.
a)
b)
ped R2 = 0.945. The contributions of steric, electrostatic, hydrophobic, hydrogen bond
donor and acceptor fields of this model were 8.2, 8.1, 25.1 and 27.7%, respectively.
The CoMSIA model with the combination of steric, electrostatic, hydrophobic and
hydrogen bond donor fields yielded the highest cross-validated R2 = 0.777 with four com-
ponents, non cross-validated R2 = 0.905, F value 66.322 and bootstrapped R2 of 0.933.
The steric, electrostatic, hydrophobic and hydrogen bond donor field contributions were
12.6, 11.0, 34.4 and 41.9%, respectively.
Combinations of steric, electrostatic and hydrogen bond donor fields yielded a CoMSIA
model with a cross-validated R2 = 0.722 with four components, non cross-validated R2=
0.852, F value 40.280 and bootstrapped R2 = 0.896. The steric, electrostatic and hydrogen
bond donor contributions were 31.3, 21.9 and 46.9%, respectively.
The models generated by various combinations of CoMSIA fields (Table VI) show
statistically significant, moderate to high, internal and external predictions, in which the
hydrogen bond donor fields were observed to be predominant over the hydrophobic
and hydrogen bond acceptor fields. The graphs of actual vs. fitted and predicted activi-
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Fig. 4a. Stereoview of CoMFA steric STDDEV*COEFF contour plots from alignment IV (analysis B).
Sterically favored areas (contribution level 80%) are represented by contours at the top of the mole-
cule as shown above. Sterically disfavored areas (contribution level 20%) are represented by poly-
hedra in the vicinity the of five-membered ring. Active compound 26 in ball and stick is shown.
Fig. 4b. Stereoview of CoMFA electrostatic STDDEV*COEFF contour plots from alignment IV (anal-
ysis B). Positively charged favored areas (contribution level 80%) are represented by polyhedra (left
corner). Negatively charged favored areas (contribution level 20%) are represented by polyhedra at
the top. Active compound 26 in ball and stick is shown.
ties for the training and test set molecules from all CoMSIA fields are shown in Figs. 5a
and 5b, respectively. The CoMSIA steric and electrostatic contours (not shown) were po-
sitioned similarly to those of the CoMFA model. The hydrogen bond donor contour
maps of CoMSIA (STDDEV*COEFF) are displayed in Fig. 6a. The contour region (80%
contribution) near 3’’-H of the 5-phenyl ring and also in the vicinity of 3’-F and 4’-H of
the 4-phenyl ring indicate the disfavored regions for hydrogen bond donor substituents.
However, the contour region (20% contribution) in the lower region of the 5-phenyl ring,
in the vicinity of 5’’-H of compound 26, indicates favored regions for hydrogen bond do-
nor substituents.
The hydrophobic contour maps of CoMSIA (STDDEV*COEFF) are displayed in Fig.
6b. The contours covering the five membered furanone ring indicate disfavored regions,
while the contours in the vicinity of 3’-F, 4’-H and 5’-H of the 4-phenyl ring of compo-
und 26 indicate favored regions.
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Fig. 5a. Graph of actual vs. predicted ac-
tivities from CoMSIA analysis with steric,
electrostatic, hydrophobic and hydrogen
bond donor fields for: a) training set mol-
ecules, b) test set molecules.
a)
b)
The CoMSIA QSAR studies give an additional structural insight into the study of
the probable binding sites of the ligand-receptor. The hydrogen bond donor favorable
contour in the vicinity of the amino group of sulfonamide moiety indicates the signifi-
cance of the proton in the hydrogen bond formation of the receptor surface. Disfavo-
rable contours in the upper region of the 4-phenyl ring indicate that hydrogen bond do-
nor substituents on this ring decrease activity (compounds 13 and 23). The hydrophobic
field favoring contours (Fig. 6b) in the upper region of the 4-phenyl ring highlight the
significance of hydrophobic groups on 3’-H, 4’-H and 5’-H of the 4-phenyl ring in the bi-
ological activity, whereas the disfavoring contours surrounding the furanone ring indi-
cate that hydrophobic substitutions on this five-membered ring decrease activity (com-
pounds 45–49).
The present results of 3D-QSAR studies are in agreement with the in vitro COX-2 in-
hibitory activity as reported by Shin et al. (21).
CONCLUSIONS
A receptor independent 3D-QSAR has been established for 5-aryl-2,2-dialkyl-4-phe-
nyl-3(2H)-furanones as selective COX-2 inhibitors employing the most widely used tech-
niques CoMFA and CoMSIA. The present studies highlight the importance of ligand ori-
entation and selection of the training set molecules in the development of statistically
significant QSAR models. CoMSIA models provided better statistical models than CoMFA,
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Fig. 6. Stereoview of CoMSIA of: a) hydrogen bond donor fields, b) hydrophobic fields.
b)
a)
which points to the significance of hydrogen bond donor and hydrophobic fields in the
selectivity and activity of these ligands in addition to steric and electrostatic fields. The
statistical significance and robustness of generated 3D-QSAR models were confirmed
using an external set of molecules. The structural requirements identified in the present
study can be utilized strategically in the design of novel, potent and selective cyclooxy-
genase-2 inhibitors as anti-inflammatory agents.
Supporting information. – SMILES format for molecules used in the QSAR analysis
C. No 1. O1CH(=CH(C(=O)C1(C)C)c2ccccc2)c3ccc(cc3)S(=O)(=O)C
C. No 2. O1CH(=CH(C(=O)C1(C)C)c2cc(ccc2)F)c3ccc(cc3)S(=O)(=O)C
C. No 3. O1CH(=CH(C(=O)C1(C)C)c2cc(ccc2)Cl)c3ccc(cc3)S(=O)(=O)C
C. No 4. O1CH(=CH(C(=O)C1(C)C)c2ccc(cc2)Br)c3ccc(cc3)S(=O)(=O)C
C. No 5. O1CH(=CH(C(=O)C1(C)C)c2cc(c(cc2)F)Cl)c3ccc(cc3)S(=O)(=O)C
C. No 6. O1CH(=CH(C(=O)C1(C)C)c2cc(cc(c2)F)F)c3ccc(cc3)S(=O)(=O)C
C. No 7. O1CH(=CH(C(=O)C1(C)C)c2cc(cc(c2)Cl)Cl)c3ccc(cc3)S(=O)(=O)C
C. No 8. O1CH(=CH(C(=O)C1(C)C)c2cc(ccc2)C(F)(F)F)c3ccc(cc3)S(=O)(=O)C
C. No 9. O1CH(=CH(C(=O)C1(C)C)c2cc(ccc2)C(C)C)c3ccc(cc3)S(=O)(=O)C
C. No 10.O1CH(=CH(C(=O)C1(C)C)c2ccc(cc2)C(C)C)c3ccc(cc3)S(=O)(=O)C
C. No 11. O1CH(=CH(C(=O)C1(C)C)c2ccc(cc2)CCCC)c3ccc(cc3)S(=O)(=O)C
C. No 12. O1CH(=CH(C(=O)C1(C)C)c2cc(ccc2)C(=O)C)c3ccc(cc3)S(=O)(=O)C
C. No 13. O1CH(=CH(C(=O)C1(C)C)c2ccc(cc2)C(=O)C)c3ccc(cc3)S(=O)(=O)C
C. No 14. O1CH(=CH(C(=O)C1(C)C)c2cc(ccc2)OC)c3ccc(cc3)S(=O)(=O)C
C. No 15. O1CH(=CH(C(=O)C1(CC)C)c2ccccc2)c3ccc(cc3)S(=O)(=O)C
C. No 16. O1CH(=CH(C(=O)C1(CC)C)c2c(cccc2)F)c3ccc(cc3)S(=O)(=O)C
C. No 17. O1CH(=CH(C(=O)C1(CC)C)c2cc(ccc2)Cl)c3ccc(cc3)S(=O)(=O)C
C. No 18. O1CH(=CH(C(=O)C1(CC)C)c2cc(cc(c2)Cl)Cl)c3ccc(cc3)S(=O)(=O)C
C. No 19. O1CH(=CH(C(=O)C1(CC)C)c2cc(ccc2)C(F)(F)F)c3ccc(cc3)S(=O)(=O)C
C. No 20. O1CH(=CH(C(=O)C1(CC)C)c2cc(ccc2)OH3)c3ccc(cc3)S(=O)(=O)C
C. No 21. O1CH(=CH(C(=O)C1(CC)CC)c2ccccc2)c3ccc(cc3)S(=O)(=O)C
C. No 22. O1CH(=CH(C(=O)C1(CC)CC)c2ccc(cc2)C(F)(F)F)c3ccc(cc3)S(=O)(=O)C
C. No 23. O1CH(=CH(C(=O)C1(CC)CC)c2cc(ccc2)C)c3ccc(cc3)S(=O)(=O)C
C. No 24. O1CH(=CH(C(=O)C1(CC)CC)c2ccc(cc2)C)c3ccc(cc3)S(=O)(=O)C
C. No 25. O1CH(=CH(C(=O)C1(C)C)c2ccccc2)c3ccc(cc3)S(=O)(=O)N
C. No 26. O1CH(=CH(C(=O)C1(C)C)c2cc(ccc2)F)c3ccc(cc3)S(=O)(=O)N
C. No 27. O1CH(=CH(C(=O)C1(C)C)c2cc(c(cc2)F)F)c3ccc(cc3)S(=O)(=O)N
C. No 28. O1CH(=CH(C(=O)C1(C)C)c2cc(ccc2)C(F)(F)F)c3ccc(cc3)S(=O)(=O)N
C. No 29. O1CH(=CH(C(=O)C1(C)C)c2ccc(cc2)C(=O)C)c3ccc(cc3)S(=O)(=O)N
C. No 30. O1CH(=CH(C(=O)C1)c2ccccc2)c3ccc(cc3F)S(=O)(=O)C
C. No 31. O1CH(=CH(C(=O)C1)c2cc(ccc2)F)c3ccc(cc3F)S(=O)(=O)C
C. No 32. O1CH(=CH(C(=O)C1)c2cc(ccc2)Cl)c3ccc(cc3F)S(=O)(=O)C
C. No 33. O1CH(=CH(C(=O)C1)c2cc(cc(c2)F)F)c3ccc(cc3F)S(=O)(=O)C
C. No 34. O1CH(=CH(C(=O)C1)c2ccccc2)c3ccc(c(c3)F)S(=O)(=O)C
C. No 35. O1CH(=CH(C(=O)C1)c2cc(ccc2)F)c3ccc(c(c3)F)S(=O)(=O)C
C. No 36. O1CH(=CH(C(=O)C1)c2cc(ccc2)Cl)c3ccc(c(c3)F)S(=O)(=O)C
C. No 37. O1CH(=CH(C(=O)C1)c2cc(cc(c2)F)F)c3ccc(c(c3)F)S(=O)(=O)C
C. No 38. O1CH(=CH(C(=O)C1)c2ccccc2)c3ccc(cc3F)S(=O)(=O)N
C. No 39. O1CH(=CH(C(=O)C1)c2cc(ccc2)F)c3ccc(cc3F)S(=O)(=O)N
C. No 40. O1CH(=CH(C(=O)C1)c2cc(cc(c2)F)F)c3ccc(cc3F)S(=O)(=O)N
C. No 41. O1CH(=CH(C(=O)C1)c2ccccc2)c3ccc(c(c3)F)S(=O)(=O)N
C. No 42. O1CH(=CH(C(=O)C1)c2cc(ccc2)F)c3ccc(c(c3)F)S(=O)(=O)N
C. No 43. O1CH(=CH(C(=O)C1)c2cc(cc(c2)F)F)c3ccc(c(c3)F)S(=O)(=O)N
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C. No 44. O1CH(=CH(C(=O)C21CCCC2)c3ccccc3)c4ccc(cc4)S(=O)(=O)C
C. No 45. O1CH(=CH(C(=O)C21CCCC2)c3cc(ccc3)F)c4ccc(cc4)S(=O)(=O)C
C. No 46. O1CH(=CH(C(=O)C21CCCC2)c3cc(ccc3)C)c4ccc(cc4)S(=O)(=O)C
C. No 47. O1CH(=CH(C(=O)C21CCCC2)c3ccc(cc3)C(C)C)c4ccc(cc4)S(=O)(=O)C
C. No 48. O1CH(=CH(C(=O)C21CCCCC2)c3ccccc3)c4ccc(cc4)S(=O)(=O)C
C. No 49. O1CH(=CH(C(=O)C21CCCCC2)c3cc(ccc3)C)c4ccc(cc4)S(=O)(=O)C
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S A @ E T A K
3D-QSAR CoMFA/CoMSIA studije derivata 5-aril-2,2-dialkil-4-fenil-
-3(2H)-furanona, kao selektivnih COX-2 inhibitora
DEVENDRA SHARAD PUNTAMBEKAR, RAJANI GIRIDHAR i MANGE RAM YADAV
Komparativna molekularna analiza polja (CoMFA) i komparativna analiza sli~nosti
molekularnih indeksa (CoMSIA) provedena je na seriji derivata 5-aril-2,2-dialkil-4-fen-
il-3(2H)-furanona kao selektivnih inhibitora ciklooksigenaze-2 (COX-2). Superimpozicija
molekularnih liganada na uzorak strukture provedena je prilagodbom korijena usred-
njenih kvadratnih udaljenosti temeljenih na udaljenostima atoma i na obliku molekule i
metodom poravnavanja unutar skupa podataka. Uklanjanjem tri spoja koji jako odstu-
paju iz po~etnog skupa od 49 molekula pove}ala se to~nost predvi|anja modela. Pos-
tavljen je statisti~ki zna~ajan model od 36 molekula, koji je provjeren na dodatnom sku-
pu od deset spojeva. Prilagodba korijena usrednjenih kvadratnih udaljenosti temeljenih
na udaljenostima atoma i na obliku molekule dala je najbolji CoMFA model sa 6 kom-
ponenata koji ima R2cv = 0,664 (kri`no provjereni kvadrat koeficijenta korelacije), R2 =
0,916, F vrijednost 47,341, kod kojega je standardna pogre{ka predvi|anja 0,360 i stan-
dardna pogre{ka procjene 0,180. Za CoMSIA model sa 4 komponente dobiveni su pa-
rametri R2cv = 0,777, R2 = 0,905, F vrijednost 66,322, standardna pogre{ka predvi|anja
0,282 i standardna pogre{ka procjene 0,185. Iz mapa obrisa dobivenih 3D-QSAR studi-
jom procijenjeni su trendovi aktivnosti za analizirane molekule. Rezultati ukazuju da
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steri~ki, elektrostatski, hidrofobni (lipofilni) supstituenti i oni koji mogu tvoriti vodiko-
vu vezu imaju zna~ajnu ulogu u inhibitornom djelovanju na COX-2 i selektivnost spo-
jeva. Podaci dobiveni ovom studijom pomo}i }e u dizajniranju novih, sna`nih i selek-
tivnih COX-2 inhibitora.
Klju~ne rije~i: 3D-QSAR, CoMFA, CoMSIA, inhibitori ciklooksigenaze-2, protuupalne tvari
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